PC-0119

PC-0119 is a small molecule drug candidate developed by Changtai Pharmaceutical (PharmaMax Corp) for the treatment of non-small cell lung cancer (NSCLC) with brain metastases. Administered as an oral tablet, it is designed to address the significant clinical challenge of intracranial disease progression in lung cancer patients. While specific molecular targets have not been publicly disclosed in the company's primary pipeline documentation, the drug is positioned within their oncology portfolio specifically for patients whose cancer has spread to the central nervous system. Changtai Pharmaceutical focuses on high-end formulations and innovative drugs, utilizing platforms for complex solid preparations and targeted delivery to improve therapeutic outcomes in oncology, respiratory, and CNS disorders.